We provide novel therapy for multiple Mitochondrial diseases

Edison Pharmaceuticals is one of a new group of pharmaceutical companies developing drug treatments for inherited mitochondrial diseases such as Leigh syndrome, Friederich’s ataxia, Leber’s hereditary optic neuropathy (LHON), and acquired mitochondrial dysfunction in Parkinson's disease and ALS.

Client Website

Edison Pharmaceuticals became part of a $545 million collaboration deal with Japan's Dainippon Sumitomo.